Oncology

Cancer is driven by rapid tumor evolution, rewiring of signaling pathways, and therapy resistance that are not always reflected at the DNA or RNA level. Proteomics provides a functional readout of tumor and microenvironmental state by directly quantifying protein abundance, pathway activation, and post-translational regulation. Comparative profiling of tumor and matched adjacent-normal tissue can identify disease-associated molecular signatures, while phosphoproteomics resolves oncogenic signaling networks and mechanisms of treatment escape. FFPE specimens enable retrospective biomarker discovery in clinically annotated cohorts, and longitudinal plasma proteomics supports minimally invasive monitoring of treatment response and disease progression. Cell-surface proteomics can further prioritize actionable targets for therapeutic modalities such as antibody-drug conjugates and T-cell engagers. Collectively, these workflows link molecular phenotype to clinical outcome and support biomarker discovery, target prioritization, and translational oncology studies.